NuVasive Announces Fourth Quarter and Full Year 2020 Financial Results

 

SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- NuVasive, Inc.,  (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended Dec. 31, 2020.

Fourth Quarter 2020

  • Net sales decreased 6.0% to $291.8 million, or 6.7% on a constant currency basis;
  • GAAP operating margin of 6.9%; Non-GAAP operating margin of 15.8%; and
  • GAAP diluted earnings per share of $0.03; Non-GAAP diluted earnings per share of $0.59.

Full Year 2020

  • Net sales decreased 10.1% to $1.051 billion, or 10.2% on a constant currency basis;
  • GAAP operating margin of 3.7%; Non-GAAP operating margin of 11.1%; and
  • GAAP diluted loss per share of $0.72; Non-GAAP diluted earnings per share of $1.23.

"NuVasive continues to see significant impact from COVID-19 on elective surgical procedures and patient sentiment, particularly within the U.S. market, which increased late in the fourth quarter," said J. Christopher Barry, chief executive officer of NuVasive. "Against a challenging 2020, we made key investments in infrastructure, talent, and innovation to unlock our ability to fulfill our long-term strategy. We are excited about the acquisition of Simplify Medical to advance our C360 portfolio and the 510(k) submission for the Pulse platform. We remain committed to delivering enhanced value to shareholders, surgeons, and employees, while helping change the lives of patients around the globe."

A full reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release.

Fourth Quarter 2020 Results
NuVasive reported fourth quarter 2020 total net sales of $291.8 million, a 6.0% decrease compared to $310.4 million for the fourth quarter 2019. On a constant currency basis, fourth quarter 2020 total net sales decreased 6.7% compared to the same period last year driven by the impact of COVID-19 on elective surgeries.

For the fourth quarter 2020, GAAP and non-GAAP gross profit was $207.2 million and $208.9 million, respectively, and GAAP and non-GAAP gross margin was 71.0% and 71.6%, respectively. These results compared to GAAP and non-GAAP gross profit of $227.1 million and GAAP and non-GAAP gross margin of 73.2%, for the fourth quarter 2019. The decline in GAAP and non-GAAP gross margin was primarily due to the decrease in net sales and incremental reserves for inventory.

The Company reported GAAP net income of $1.7 million, or diluted earnings per share of $0.03, for the fourth quarter 2020 compared to GAAP net income of $29.9 million, or diluted earnings per share of $0.55, for the fourth quarter 2019. On a non-GAAP basis, the Company reported net income of $30.4 million, or diluted earnings per share of $0.59, for the fourth quarter 2020 compared to non-GAAP net income of $38.5 million, or diluted earnings per share of $0.73, for the fourth quarter 2019.

Free cash flow for the quarter ended Dec. 31, 2020, was $44.8 million compared to $46.3 million in the prior year period.

Full Year 2020 Results
NuVasive reported full year 2020 total net sales of $1.051 billion, a 10.1% decrease compared to $1.168 billion for the full year 2019. On a constant currency basis, full year 2020 total net sales decreased 10.2% compared to the full year 2019, which reflects the impact of the COVID-19 pandemic.

For the full year 2020, GAAP and non-GAAP gross profit was $729.0 million and $730.7 million, respectively, and GAAP and non-GAAP gross margin was 69.4% and 69.5%, respectively. These results compared to GAAP and non-GAAP gross profit of $855.7 million, and GAAP and non-GAAP gross margin of 73.3% for the full year 2019. The decrease in GAAP and non-GAAP gross margin was primarily a result of incremental reserves for inventory attributed to projected demand for certain spinal hardware products impacted by COVID-19.

The Company reported GAAP net loss of $37.2 million, or diluted loss per share of $0.72, for the full year 2020 compared to GAAP net income of $65.2 million, or diluted earnings per share of $1.23, for the full year 2019. On a non-GAAP basis, the Company reported net income of $63.8 million, or diluted earnings per share of $1.23, for the full year 2020 compared to non-GAAP net income of $129.8 million, or diluted earnings per share of $2.47, for the full year 2019. See the "Reconciliation of GAAP to Non-GAAP Financial Measures" table for a reconciliation of these GAAP and non-GAAP financial measures.

Cash, cash equivalents, and investments were $1.030 billion as of Dec. 31, 2020, compared to $213 million reported as of Dec. 31, 2019.

Simplify Medical
In a separate news release, NuVasive announced it has acquired Simplify Medical, a privately held company and developer of the Simplify® Cervical Artificial Disc for cervical total disc replacement (cTDR), as of Feb. 24, 2021. The transaction provides NuVasive with the most clinically effective technology in the cTDR procedure segment and further distinguishes NuVasive's C360 cervical portfolio in the market.

Supplementary Financial Information
For additional financial detail, please visit the Investor Relations section of the Company's website at www.nuvasive.com to access Supplementary Financial Information.

Reconciliation of GAAP to Non-GAAP Information
Management uses certain non-GAAP financial measures such as non-GAAP diluted earnings (loss) per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating margin, which exclude amortization of intangible assets, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses from strategic investments, gains and losses from changes in fair value of derivatives and non-cash interest expense (excluding debt issuance cost). Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency utilizes an exchange rate that eliminates fluctuations when calculating financial performance numbers. The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses on strategic investments, gains and losses from changes in fair value of derivatives and other significant one-time items.

Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measure.

 

For the Three Months Ended December 31, 2020

 

Reconciliation of GAAP to Non-GAAP Financial Measures

 

(Unaudited - in thousands, except per share data)

               
   

Gross Profit

Operating
Profit

Net Income

Diluted
EPS

Diluted
WASO5

Net Income to
Adjusted EBITDA

 

Reported GAAP

$        207,179

$          20,235

$            1,692

$          0.03

51,870

$                           1,692

 

% of net sales

71.0%

6.9%

       
 

Amortization of intangible assets

 

12,576

12,576

     
 

Litigation related expenses and settlements1

 

1,310

1,310

   

1,310

 

Business transition costs2

 

8,337

8,337

   

8,337

 

European medical device regulation3

1,706

3,614

3,614

   

3,614

 

Non-cash interest expense on convertible notes

   

12,844

     
 

Net gain on strategic investments

   

(10)

   

(10)

 

Tax effect of adjustments4

   

(9,989)

     
 

Interest expense/(income), net

         

21,136

 

Income tax benefit

         

(628)

 

Depreciation and amortization

         

34,840

 

Non-cash stock-based compensation

         

7,706

 

Adjusted Non-GAAP

$        208,885

$          46,072

$          30,374

$          0.59

51,870

$                         77,997

 

% of net sales

71.6%

15.8%

     

26.7%

               

1

Represents expenses associated with certain ongoing litigation matters, including infringement of the Company's intellectual property.

2

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

3

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

4

Represents the impact from tax affecting the adjustments above at their statutory tax rate. The impact of these adjustments to the tax rate results in an annual tax rate of ~22% on a GAAP basis and ~24% on a non-GAAP basis.

5

Adjusted non-GAAP diluted WASO excludes the impact of all dilutive securities, including convertible notes for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

   
 

For the Year Ended December 31, 2020

 

Reconciliation of GAAP to Non-GAAP Financial Measures

 

(Unaudited - in thousands, except per share data)

               
   

Gross Profit

Operating
Profit

Net (Loss) Income

Diluted
EPS

Diluted
WASO7

Net (Loss) to
Adjusted EBITDA

 

Reported GAAP

$        728,951

$          38,303

$        (37,153)

$        (0.72)

51,416

$                       (37,153)

 

% of net sales

69.4%

3.7%

       
 

Amortization of intangible assets

 

51,726

51,726

     
 

Litigation related expenses and settlements1

 

6,996

6,996

   

6,996

 

Business transition costs2

 

10,878

10,878

   

10,878

 

Purchase of in-process research and development3

 

1,011

1,011

   

1,011

 

European medical device regulation4

1,706

7,693

7,693

   

7,693

 

Non-cash interest expense on convertible notes

   

40,866

     
 

Net loss on strategic investments

   

268

   

268

 

Net loss recognized on change in fair value of derivatives5

   

12,301

   

12,301

 

Tax effect of adjustments6

   

(30,823)

     
 

Interest expense/(income), net

         

68,994

 

Income tax benefit

         

(10,392)

 

Depreciation and amortization

         

140,937

 

Non-cash stock-based compensation

         

17,457

 

Adjusted Non-GAAP

$        730,657

$        116,607

$          63,763

$          1.23

51,992

$                       218,990

 

% of net sales

69.5%

11.1%

     

20.8%

               

1

Represents expenses associated with certain ongoing litigation matters, including infringement of the Company's intellectual property.

2

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

3

Purchase of an in-process research and development asset which had no future alternative use.

4

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

5

Represents the net change in fair value of the Company's derivative asset and liability associated with the 2023 Notes.

6

Represents the impact from tax affecting the adjustments above at their statutory tax rate. The impact of these adjustments to the tax rate results in an annual tax rate of ~22% on a GAAP basis and ~24% on a non-GAAP basis.

7

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

   
 

For the Three Months Ended December 31, 2019

 

Reconciliation of GAAP to Non-GAAP Financial Measures

 

(Unaudited - in thousands, except per share data)

               
   

Gross Profit

Operating
Profit

Net Income

Diluted
EPS

Diluted
WASO5

Net Income to
Adjusted EBITDA

 

Reported GAAP

$        227,098

$          42,166

$          29,876

$          0.55

54,638

$                         29,876

 

% of net sales

73.2%

13.6%

       
 

Amortization of intangible assets

 

12,599

12,599

     
 

Litigation related expenses and settlements1

 

818

818

   

818

 

Business transition costs2

 

(7,141)

(7,141)

   

(7,141)

 

European medical device regulation3

 

2,384

2,384

   

2,384

 

Non-cash interest expense on convertible notes

   

4,492

     
 

Tax effect of adjustments4

   

(4,513)

     
 

Interest expense/(income), net

         

9,147

 

Income tax expense

         

3,271

 

Depreciation and amortization

         

34,348

 

Non-cash stock-based compensation

         

10,285

 

Adjusted Non-GAAP

$        227,098

$          50,826

$          38,515

$          0.73

52,979

$                         82,988

 

% of net sales

73.2%

16.4%

     

26.7%

               

1

Represents expenses associated with certain ongoing litigation matters, including infringement of the Company's intellectual property.

2

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

3

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

4

Represents the impact from tax affecting the adjustments above at their statutory tax rate. The impact of these adjustments to the tax rate results in an annual tax rate of ~19% on a GAAP basis and ~21% on a non-GAAP basis.

5

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

   
 

For the Year Ended December 31, 2019

 

Reconciliation of GAAP to Non-GAAP Financial Measures

 

(Unaudited - in thousands, except per share data)

               
   

Gross Profit

Operating
Profit

Net Income

Diluted
EPS

Diluted
WASO5

Net Income to
Adjusted EBITDA

 

Reported GAAP

$        855,713

$        123,050

$          65,234

$          1.23

53,160

$                         65,234

 

% of net sales

73.3%

10.5%

       
 

Amortization of intangible assets

 

51,097

51,097

     
 

Litigation related expenses and settlements1

 

7,794

7,794

   

7,794

 

Business transition costs2

 

(1,995)

(1,995)

   

(1,995)

 

European medical device regulation3

 

5,069

5,069

   

5,069

 

Non-cash interest expense on convertible notes

   

17,617

     
 

Net loss on strategic investments

   

4,767

   

4,767

 

Tax effect of adjustments4

   

(19,782)

     
 

Interest expense/(income), net

         

36,608

 

Income tax expense

         

15,283

 

Depreciation and amortization

         

135,593

 

Non-cash stock-based compensation

         

30,732

 

Adjusted Non-GAAP

$        855,713

$        185,015

$        129,801

$          2.47

52,629

$                       299,085

 

% of net sales

73.3%

15.8%

     

25.6%

               

1

Represents expenses associated with certain ongoing litigation matters, including infringement of the Company's intellectual property.

2

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

3

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

4

Represents the impact from tax affecting the adjustments above at their statutory tax rate. The impact of these adjustments to the tax rate results in an annual tax rate of ~19% on a GAAP basis and ~21% on a non-GAAP basis.

5

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

               

Investor Conference Call
NuVasive will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the fourth quarter and full year ended Dec. 31, 2020, as well as its acquisition of Simplify Medical. The dial-in numbers are 1-800-954-0604 for domestic callers and 1-312-281-1210 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, the call will remain available on NuVasive's website through March 25, 2021. In addition, a telephone replay of the call will be available until March 4, 2021. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 21990639.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive has approximately 2,700 employees and operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. Forward-looking statements include, but are not limited to, statements about the potential benefits of the acquisition of Simplify Medical, including the expected impact on future financial and operating results, and post-acquisition plans and intentions. In addition, this news release contains selected financial results from the fourth quarter and full year 2020. The Company's results for the fourth quarter and full year 2020 are prior to the completion of review and audit procedures by the Company's external auditors and are subject to adjustment. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, the impact of the COVID-19 pandemic on the Company's business and financial results; the Company's ability to maintain operations to support its customers and patients in the near-term and to capitalize on future growth opportunities; the risk that Simplify Medical will not be integrated successfully and that benefits from the acquisition may not be fully realized or may take longer to realize than expected; risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel. Additional risks and uncertainties that may affect future results are described in the Company's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

NuVasive, Inc. 

Consolidated Statements of Operations 

(in thousands, except per share data)

                 
   

Three Months Ended December 31,

 

Year Ended December 31,

   

2020

 

2019

 

2020

 

2019

   

(Unaudited)

 

(Unaudited)

       

Net sales:

               

Products

 

$  264,267

 

$  279,234

 

$   950,189

 

$  1,044,569

Services

 

27,540

 

31,120

 

100,393

 

123,501

Total net sales

 

291,807

 

310,354

 

1,050,582

 

1,168,070

Cost of sales (excluding below amortization of intangible assets):

               

Products

 

65,742

 

63,211

 

247,809

 

232,474

Services

 

18,886

 

20,045

 

73,822

 

79,883

Total cost of sales

 

84,628

 

83,256

 

321,631

 

312,357

Gross profit

 

207,179

 

227,098

 

728,951

 

855,713

Operating expenses:

               

Selling, general and administrative

 

144,260

 

160,365

 

547,195

 

611,181

Research and development

 

21,771

 

19,109

 

79,838

 

72,380

Amortization of intangible assets

 

12,576

 

12,599

 

51,726

 

51,097

Purchase of in-process research and development

 

 

 

1,011

 

Business transition costs

 

8,337

 

(7,141)

 

10,878

 

(1,995)

Total operating expenses

 

186,944

 

184,932

 

690,648

 

732,663

Interest and other expense, net:

               

Interest income

 

166

 

561

 

1,472

 

1,917

Interest expense

 

(21,302)

 

(9,708)

 

(70,466)

 

(38,525)

Other income (expense), net

 

1,965

 

128

 

(16,854)

 

(5,925)

Total interest and other expense, net

 

(19,171)

 

(9,019)

 

(85,848)

 

(42,533)

Income (loss) before income taxes

 

1,064

 

33,147

 

(47,545)

 

80,517

Income tax benefit (expense)

 

628

 

(3,271)

 

10,392

 

(15,283)

Consolidated net income (loss)

 

$      1,692

 

$    29,876

 

$   (37,153)

 

$       65,234

                 

Net income (loss) per share:

               

Basic

 

$        0.03

 

$        0.57

 

$       (0.72)

 

$           1.26

Diluted

 

$        0.03

 

$        0.55

 

$       (0.72)

 

$           1.23

Weighted average shares outstanding:

               

Basic

 

51,343

 

52,117

 

51,416

 

51,956

Diluted

 

51,870

 

54,638

 

51,416

 

53,160

 

NuVasive, Inc. 

Consolidated Balance Sheets 

(in thousands, except par value data) 

   

December 31,

   

2020

 

2019

ASSETS

       

Current assets:

       

Cash and cash equivalents

 

$     856,869

 

$     213,034

Short-term marketable securities

 

173,145

 

Accounts receivable, net of allowances of $20,631and $17,019, respectively

 

207,071

 

211,532

Inventory, net

 

300,623

 

312,419

Prepaid income taxes

 

4,727

 

10,434

Prepaid expenses and other current assets

 

19,749

 

16,917

Total current assets

 

1,562,184

 

764,336

Property and equipment, net

 

286,369

 

266,318

Intangible assets, net

 

152,264

 

201,092

Goodwill

 

559,553

 

561,064

Operating lease right-of-use assets

 

102,270

 

66,932

Deferred tax assets

 

15,755

 

9,162

Restricted cash and investments

 

1,494

 

1,494

Other assets

 

13,193

 

14,892

Total assets

 

$  2,693,082

 

$  1,885,290

LIABILITIES AND EQUITY

       

Current liabilities:

       

Accounts payable and accrued liabilities

 

$     110,401

 

$       97,160

Contingent consideration liabilities

 

7,289

 

15,727

Accrued payroll and related expenses

 

63,421

 

86,458

Operating lease liabilities

 

7,875

 

5,567

Income tax liabilities

 

2,073

 

2,005

Senior convertible notes

 

645,303

 

Total current liabilities

 

836,362

 

206,917

Long-term senior convertible notes

 

766,226

 

623,298

Deferred tax liabilities

 

2,807

 

14,655

Operating lease liabilities

 

111,634

 

73,153

Other long-term liabilities

 

52,438

 

52,060

Commitments and contingencies

       

Redeemable equity component of senior convertible notes

 

4,697

 

Stockholders' equity:

       

Preferred stock, $0.001 par value; 5,000 shares authorized, none outstanding

 

 

Common stock, $0.001 par value; 150,000 and 120,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; 57,945 shares issued and 51,376 outstanding at December 31, 2020; 57,525 issued and 52,145 outstanding at December 31, 2019

 

62

 

62

Additional paid-in capital

 

1,550,001

 

1,429,854

Accumulated other comprehensive loss

 

(7,585)

 

(9,418)

Retained earnings

 

45,322

 

82,475

Treasury stock at cost; 6,569 shares and 5,380 shares at December 31, 2020 and December 31, 2019, respectively

 

(668,882)

 

(587,766)

Total equity

 

918,918

 

915,207

Total liabilities and equity

 

$  2,693,082

 

$  1,885,290

         

 

NuVasive, Inc. 

Consolidated Statements of Cash Flows 

(in thousands) 

         
   

Year Ended December 31,

   

2020

 

2019

Operating activities:

       

Consolidated net (loss) income

 

$  (37,153)

 

$    65,234

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

       

Depreciation and amortization

 

140,937

 

135,593

Purchase of in-process research and development

 

1,011

 

Deferred income taxes

 

(18,007)

 

5,844

Amortization of non-cash interest

 

48,986

 

21,288

Stock-based compensation

 

18,145

 

30,297

Net loss on strategic investments

 

268

 

4,767

Net loss recognized on change in fair value of derivatives

 

12,301

 

Reserves on current assets

 

53,902

 

18,382

Other non-cash adjustments

 

16,876

 

5,650

Changes in operating assets and liabilities, net of effects from acquisitions:

       

Accounts receivable

 

3,030

 

(16,407)

Inventory

 

(40,765)

 

(54,872)

Prepaid expenses and other current assets

 

(4,986)

 

(4,622)

Accounts payable and accrued liabilities

 

8,756

 

(3,924)

Accrued payroll and related expenses

 

(23,654)

 

24,256

Income taxes

 

6,264

 

3,804

Net cash provided by operating activities

 

185,911

 

235,290

Investing activities:

       

Acquisitions and investments

 

 

(4,100)

Proceeds from other investments

 

1,143

 

Purchases of intangible assets

 

(3,860)

 

(7,501)

Purchases of property and equipment

 

(105,729)

 

(122,883)

Purchases of marketable securities

 

(233,488)

 

Proceeds from sales and maturities of marketable securities

 

60,000

 

Net cash used in investing activities

 

(281,934)

 

(134,484)

Financing activities:

       

Proceeds from the issuance of common stock

 

6,170

 

6,415

Payment of contingent consideration

 

(7,053)

 

(809)

Purchase of treasury stock

 

(80,665)

 

(14,478)

Proceeds from issuance of convertible debt, net of issuance costs

 

873,848

 

Proceeds from sale of warrants

 

93,915

 

Purchases of convertible note hedges

 

(147,825)

 

Other financing activities

 

(1,734)

 

2,228

Net cash provided by (used in) financing activities

 

736,656

 

(6,644)

Effect of exchange rate changes on cash

 

3,202

 

131

Increase in cash, cash equivalents and restricted cash

 

643,835

 

94,293

Cash, cash equivalents and restricted cash at beginning of period

 

214,528

 

120,235

Cash, cash equivalents and restricted cash at end of period

 

$  858,363

 

$  214,528

         

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasive-announces-fourth-quarter-and-full-year-2020-financial-results-301235934.html

SOURCE NuVasive, Inc.

 
 
Company Codes: NASDAQ-NMS:NUVA
 

Back to news